Upregulation of Id3 inhibits cell proliferation and induces apoptosis in A549/DDP human lung cancer cells in vitro

FANGFANG CHEN¹, QINFEI ZHAO¹, SHUXIA WANG¹, HAIYONG WANG¹ and XIAOJUN LI¹,²

¹Center of Clinical Laboratory Science, Jinling Hospital, School of Medicine, Southern Medical University, Nanjing, Jiangsu 210002; ²State Key Laboratory of Analytical Chemistry for Life Science, Department of Chemistry, Nanjing University, Nanjing, Jiangsu 210093, P.R. China

Received May 19, 2015; Accepted March 23, 2016

DOI: 10.3892/mmr.2016.5221

Abstract. Inhibitor of DNA binding (Id)3 is a member of the Id multigene family of dominant-negative helix-loop-helix transcription factors, which function as oncogenes or tumor suppressors in human cancers. Its upregulation was recently shown to have inhibitory effects on lung cancer, which is the leading cause of cancer-associated mortality worldwide. As drug resistance represents a major bottleneck of cancer therapy, the present study assessed the ability of Id3 to inhibit cisplatin-resistant A549 lung adenocarcinoma cells (A549/DDP). A549/DDP cells were transiently transfected with enhanced green fluorescence protein overexpression plasmid (pEGFP) or Id3 overexpression plasmid (Id3/pEGFP), which was confirmed by confocal fluorescence microscopy, PCR and western blot analysis. The effects of Id3 on the viability and apoptosis of A549/DDP were determined using an MTT assay, fluorescence microscopy with Hoechst 33258 staining and flow cytometry following Annexin V/propidium iodide double staining. The results revealed that overexpression of Id3 significantly inhibited the proliferation and viability of A549/DDP cells in a time-dependent manner. Furthermore, overexpression of Id3 significantly increased the apoptotic rate of A549/DDP cells from 2.73 to 16.92%, confirming the implication of Id3 in the negative control of tumour growth. The results of the present study revealed that overexpression of Id3 may serve as a novel strategy for inhibiting cisplatin-sensitive lung cancer. Further experiments will be performed to determine whether Id3 overexpression could enhance the sensitivity of lung cancer cells to DDP.

Introduction

Non-small-cell lung cancer (NSCLC) is the most frequent type of lung cancer and the most common cause of cancer-associated mortality (1). The poor outcome of NSCLC and patient survival are partly due to the development of drug resistance. At present, cisplatin-based chemotherapy is recommended as the first-line treatment for advanced NSCLC. Despite extensive research on its resistance mechanisms, pre-clinical data have not been incorporated into the selection of NSCLC patients or tailored treatment regimens in clinical trials. The current understanding of the molecular mechanisms of NSCLC and its chemoresistance requires to be expanded and applied for its treatment. It is important to identify novel biomarkers and therapeutic targets for NSCLC and provide a rationale to overcome the current therapeutic plateau.

Inhibitor of differentiation/DNA binding (Id) proteins, which are negative regulators of basic helix-loop-helix (bHLH) transcription factors, function as dominant-negative inhibitors of E-proteins by inhibiting their ability to bind DNA (2,3). Four members of the Id family, ID1-4, occur in vertebrates. Id proteins have crucial roles in the coordinated regulation of a variety of cellular processes, including cell growth, differentiation, apoptosis, tumorigenesis and carcinogenesis (4-6). Numerous studies have shown that the expressional regulation and functions of Ids are controlled by complex mechanisms, which are distinct for various cancer cell types and developmental stages (7-9).

The Id3 gene is likely to have similar biological behaviors to those of other Ids, which have an important role in cell apoptosis. In B-lymphocyte progenitors, Id3 was found to induce cell growth arrest and caspase-3-dependent apoptosis (10). In immortalized human keratinocytes, Id3 as the apical gene in the mitochondrial pathway of cell death, is able to induce caspase-3- and -9-dependent apoptosis and mediate their UVB sensitization (11).

Id3 has been implicated in mediating apoptosis induced by cisplatin, a DNA-damaging chemotherapeutic agent. Cisplatin induced upregulation of Id3 mRNA, and ectopic expression of Id3 sensitized MG-63 sarcoma cells to cisplatin-induced caspase-3 activation and growth inhibition (12). However, the exact induction mechanism was not described. Previous studies by our group showed that Id3 was downregulated in
A549 human lung adenocarcinoma epithelial cells and that ectopic overexpression of Id3 in A549 cells inhibited their proliferation and induced apoptosis in vitro, as well as reducing tumor growth in vivo (13,14). These results suggested that Id3, as an upstream gene of the apoptotic signaling cascade, can induce cell apoptosis.

The present study was the first to perform plasmid-mediated overexpression of Id3 in cisplatin-resistant A549 cells (A549/DDP) to assess its effect on the cells’ proliferation and apoptotic rate. The results suggested that ectopic expression of Id3 may represent a promising approach for inhibiting chemoresistant NSCLC cells.

Materials and methods

Cell lines and culture. The cisplatin-resistant A549/DDP cell line and native A549 cells were purchased from the Cancer Institute of the Chinese Academy of Medical Sciences (Beijing, China). Cells were cultured in RPMI-1640 medium (HyClone Laboratories, Inc., Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS; HyClone Laboratories, Inc.), 100 U/ml penicillin and 100 mg/ml streptomycin (HyClone Laboratories, Inc.) in an atmosphere containing 5% CO₂ at 37°C. In all experiments, exponentially growing cells were used.

Transient transfection. Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) was used for transfection following the manufacturer’s instructions. In brief, A549/DDP cells (0.5-2x10⁵/well in 400 µl medium) were seeded into 24-well plates and incubated for 24 h for attachment to reach 90-95% confluence. Enhanced green fluorescence protein-expressing plasmid (pEGFP) or Id3/pEGFP (0.8 µg) and Lipofectamine 2000 (2 µl) were each diluted separately in 50 µl serum-free Opti-MEM (Gibco BRL, Thermo Fisher Scientific, Inc.) and incubated for 5 min at room temperature, followed by mixing of the respective plasmid and Lipofectamine 2000 solutions and incubation at room temperature for 20 min. The cells were then incubated with this mixture (100 µl) at 37°C for 12-72 h depending on the specific experiment and then subjected to further analysis.

Proliferation assay. The effects of DPP (Sigma-Aldrich, St. Louis, MO, USA) on native A549 and A594/DDP cells as well as the effects of Id3/pEGFP on A549/DDP cells were assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. In brief, cells were seeded into 96-well plates at 5x10⁴ cells/well and allowed to attach overnight. Subsequently DPP was added at various concentrations (0, 0.5, 1, 2, 5, 10, 15, 20, 30, 40 and 80 µg/ml), followed by incubation for 24 h. In another experiment, A594/DDP cells were transfected with pEGFP or Id3/pEGFP as described above for 12, 24, 48 or 72 h. The cell viability was then assessed by addition of 0.5 mg/ml MTT (Sigma-Aldrich), and cells were incubated at 37°C for 4 h. Then culture medium was removed and 150 µl dimethyl sulfoxide (Sigma-Aldrich) was added, followed by agitation for 10 min. The absorbance at 570 nm (OD₅₇₀) was measured by using a Multiskan MS microplate reader (Labsystems Diagnostics Oy, Vantaa, Finland) with a reference wavelength of 650 nm. The experiment was repeated three times to generate a growing curve using the following formula: Proliferation rate (%) = OD₅₇₀ (experimental group) / OD₅₇₀ (control group) x 100%.

Reverse-transcription polymerase chain reaction (RT-PCR). Total RNA was extracted from cells using TRIzol® reagent (Invitrogen). Total RNA (1 µg) was reverse-transcribed using the RevertAid First Strand cDNA Synthesis kit (Fermentas, Vilnius, Lithuania). PCR was performed in a total volume of 25 µl containing 12.5 µl Premix Ex Taq loading dye mix (Takara Bio Inc., Otsu, Japan), 7.5 µl double-distilled water, 1.5 µl Id3 forward primer (5'-AGTGAAGCCTGAGC CGGT-3'), 1.5 µl Id3 reverse primer (5'-TTTGGCCTCCTG CGGT-3') (both purchased from Invitrogen; Thermo Fisher Scientific, Inc.) and 2 µl cDNA. Complementary DNA was amplified under the following reaction conditions: 94°C for 5 min, followed by 35 amplification cycles of 94°C for 50 sec, 55°C for 50 sec, 70°C for 50 sec and final elongation at 72°C for 5 min. Three independent experiments were performed to confirm reproducibility of the results.

Western blot analysis. A549/DDP cells were cultured in six-well plates, transfected with pEGFP/Id3 for 24 h, washed twice with ice-cold phosphate-buffered saline (PBS; pH 7.2), lysed in 200 µl radioimmunoprecipitation assay buffer (Beyotime Institute of Biotechnology, Inc., Haimen, China) and recovered with a cell scraper. Protein concentrations were determined using the Enhanced BCA Protein Assay kit (Beyotime Institute of Biotechnology, Inc.). Samples (20 µg) of the cellular lysate were denatured and fractionated by sodium dodecyl sulfate polyacrylamide gel electrophoresis [SDS-PAGE; 12% (w/v) polyacrylamide gel] and transferred onto a polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA) by semi-dry blotting (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The membranes were blocked with Tris-buffered saline containing Tween 20 (TBST; Beyotime Institute of Biotechnology, Inc.) with 5% (w/v) non-fat milk for 2 h and incubated with mouse monoclonal anti-hId3 (1:1000 dilution; cat. no. ab55269; Abcam, Cambridge, MA, USA) or rabbit anti-β-actin (1:800 dilution; cat. no. sc-10731; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) for 1 h at room temperature and overnight at 4°C. After washing, the membranes were incubated with horseradish peroxidase (HRP)-conjugated goat anti-mouse immunoglobulin (IgG) (1:400 dilution; Santa Cruz Biotechnology, Inc.), HRP-conjugated goat anti-rabbit IgG (1:300 dilution; Santa Cruz Biotechnology, Inc.), or HRP-conjugated goat anti-rabbit IgG (1:300 dilution; Santa Cruz Biotechnology, Inc.) for 2 h at room temperature. Antibody binding was detected using an enhanced chemiluminescence detection system (Millipore). The intensities of bands were measured using Quantity One® software (version 170-9600; Bio-Rad Laboratories, Inc.) with normalization to β-actin as the internal control.

Flow cytometric analysis. Apoptosis was quantified using AnnexinV-fluorescein isothiocyanate (FITC)/propidium iodide (PI) staining followed by flow cytometry. A549/DDP cells (3.5x10⁴ cells/well) were cultured in six-well plates to 90% confluency, transfected for 24 h, collected by trypsinization, washed twice with PBS and suspended in 100 µl binding buffer containing 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid/NaOH (pH 7.4), 140 mM NaCl and 2.5 mM CaCl₂ (BD Biosciences,
A549/DPP cells (19.38±1.66 µg/ml) was 3-4-fold increased compared to that of the native A549 cells (5.32±3.11 µg/ml), confirming the drug resistance of the A549/DPP cell line.

**Overexpression of Id3 in A549/DDP cells**. Transfection with the eukaryotic expression vectors pEGFP or Id3/pEGFP for 24 h was successful, as indicated by confocal fluorescence microscopy (Fig. 2A). Furthermore, the overexpression of Id3 in A549/DDP cells transfected with Id3/pEGFP for 24 h was confirmed at the mRNA level by RT-PCR (Fig. 2B) and at the protein level by western blotting (Fig. 2C). There was significant difference in Id3 transfected cells (P<0.05), but there was no significant difference in the EGFP vector group and blank control group (P>0.05).

**Id3 inhibits the proliferation of A549/DDP cells**. To investigate the effects of Id3 overexpression on the proliferation of A549/DDP cells, an MTT assay was performed. MTT analysis revealed that transfection with Id3/pEGFP for 12, 24, 48 or 72 h inhibited the proliferation of A549/DDP cells in a time-dependent manner, but there was no trend in pEGFP-transfected group (Fig. 3).

**Id3 induces apoptosis in A549/DDP cells**. Fluorescence microscopy following Hoechst 33258 staining revealed that A549/DDP cells transfected with Id3/pEGFP presented with apoptotic features, including partially ruptured nuclei as well as cells of different sizes and with shrunken or distorted nuclei, as indicated by conglomerated fluorescence that presented the appearance of grains. In comparison, only a very small proportion of cells in the pEGFP-transfected and control groups showed these apoptotic features (Fig. 4A). Flow cytometric analysis further confirmed the above results: As shown in Fig. 4B and C, increased levels of early apoptotic cells (16.92±8.72%) were observed in the Id3/pEGFP-transfected group, while the proportion of early apoptotic cells in the untreated control or pEGFP-transfected groups was markedly lower (2.73±2.54 and 3.07±5.03%, respectively). All of these results demonstrated that ectopic expression of Id3 induced apoptosis in A549/DDP cells.

**Discussion**

Lung cancer is the most frequent cancer type worldwide and its incidence increases by 0.5% per year (15). Despite major advances in disease management, chemotherapy and radiotherapy, almost 80% of all patients with lung cancer succumb to the disease within 1 year of diagnosis and long-term survival is achieved in only 5-10% of all cases (15,16). The major obstacle in lung cancer chemotherapy is inherent and acquired drug resistance of the cancer cells (17,18), which limits the efficacy of chemotherapy. Therefore, it is important to identify novel biomarkers for lung cancer which may be utilized as therapeutic targets.

Id3 is a member of the Id family of proteins and is a helix-loop-helix transcription factor. The tumor suppressor function of Id3 has been reported in a variety of cancer types, including hepatocellular carcinoma (19), prostate cancer (20) and colorectal adenocarcinoma (21). Forced expression of Id3 in head and neck squamous cell carcinoma cells reduced...
CHEN et al: ID3 INHIBITS CELL PROLIFERATION AND INDUCES APOPTOSIS IN A549/DDP CELLS

their invasiveness interference with the transcription of matrix metalloproteinase 2 (22). In primary human colorectal adenocarcinomas, the expression of Id1, Id2 and Id3 was found to be significantly increased compared with that in normal mucosa and correlated with the presence of mutated p53 (23,24). Numerous studies have assessed the role of Id3 in various cancer types (25,26). Previous studies by our group have shown that upregulation of Id3 inhibited the proliferation and induced apoptosis in A549 cells in vitro and in vivo (13,14), while further study is required to determine the underlying mechanisms. Therefore, ectopic expression of Id3 may represent a novel strategy for treating NSCLC. However, the effects of Id3 on the drug resistant A549/DDP human lung cancer cell line have not been previously reported, to the best of our knowledge.

Apoptosis is a form of programmed cell death, which maintains the healthy survival/death balance in metazoan cells, while it is generally circumvented by cancer cells (27). Apoptosis induction is an important mechanism of action of anti-cancer agents. Numerous studies have focused on the manipulation of specific genes to enhance the sensitivity of cancer cells to drugs such as the DNA-damaging agent cisplatin (28,29). High levels of Id3 have been indicated to have a role in drug resistance and disease progression and Id3 has been implicated in apoptosis in response to cisplatin. Treatment with cisplatin increased the mRNA levels of Id3 in MG-63 sarcoma cells, while ectopic expression of Id3 sensitized them to cisplatin-induced caspase-3 activation and growth inhibition (12). The results of the present study showed that overexpression of Id3 significantly inhibited the growth of A549/DDP cells and induced apoptosis, indicating that high levels of Id3 protein expression may be a potential target for cisplatin resistance of lung adenocarcinoma cells. The effects of DDP on A549/DDP cells transfected with Id3/pEGFP will be investigated in future studies.

The expression of Id3 is dependent on the cell type and developmental stage. When different types of cell received different types of stimulation, they regulated the expression of Id3 through different mechanisms and signal transduction pathways. Studies by Langenfeld et al (30,31) showed that inhibition of bone morphogenetic protein signaling by the selective antagonist DMH2 decreased the expression of Id1/Id3

Figure 2. Overexpression of Id3 in A549/DDP cells. (A) Immunofluorescence was used to detect Id3 expression via EGFP. Images shown are representative of three independent experiments (magnification, x200), (B and C) 24 h after transfection of A549/DDP cells with pEGFP or Id3/pEGFP, Id3 expression was detected (B) at the mRNA level by reverse-transcription polymerase chain reaction analysis with GAPDH used as an internal control and (C) at the protein level by western blot analysis with β-actin used as an internal control. Lanes: 1, Id3/pEGFP transfectants; 2, pEGFP transfectants; 3, untreated control. Data from one of three or more representative experiments are shown. EGFP, enhanced green fluorescence protein; Id3, inhibitor of DNA binding 3.

Figure 3. Time-dependent growth inhibitory effects of Id3 on A549/DDP cells. MTT analysis of the inhibitory effects of Id3 on A549/DDP cell proliferation at 12, 24, 48 and 72 h following transfection with Id3/pEGFP or pEGFP. Each experiment was performed in triplicate, and bars represent the mean ± standard deviation. The proliferation or survival of A549/DDP cells was markedly inhibited by Id3/pEGFP. EGFP, enhanced green fluorescence protein; Id3, inhibitor of DNA binding 3.
and induced significant growth inhibition of lung cancer cells. Furthermore, silencing of Id3 significantly decreased the proliferation of lung cancer cells and induced cell death. However, cells stably overexpressing Id3 were resistant to growth suppression and induction of cell death induced by DMH2. By contrast, Chen et al (32) reported that suppression of Id3 expression in SCLC cells produced a significant reduction in the proliferative rate and colony formation. Another study demonstrated that co-expression of Id1 and Id3 correlated with poor clinical outcome in patients with stage III-N2 NSCLC treated with definitive chemoradiotherapy (33). The complexity of the regulatory mechanism of Id3 expression determines the diversity of its functions. These diverse effects of Id3 in tumor cells may depend on the tumor type and stage.

The present study, for the first time, explored the effects of Id3 on the cisplatin-resistant A549/DDP human lung cancer cell line. Ectopic overexpression of Id3 in A549/DDP significantly inhibited the proliferation was induced apoptosis in vivo. Next, it will be explored whether Id3 gene expression is associated with cisplatin resistance in non-small-cell lung cancer, and whether Id3 overexpression can enhance the sensitivity of lung adenocarcinoma cells to DDP. Further study is required to characterize the underlying mechanisms and the apoptotic signaling pathways triggered by Id3; furthermore, the effects of Id3 upregulation require verification in vivo. In addition, the roles or association with other Id (Id1) genes may be assessed in further studies. However, the results of the present study indicated that Id3 may serve as a novel biomarker for NSCLC and that its overexpression may represent a novel therapeutic strategy for cisplatin-resistant NSCLC cells.

Acknowledgements

This work was supported by a grant from the National Natural Science Foundation of China (no. 81171652). The authors would like to thank International Science Editing (Shannon, Ireland) for language editing of the manuscript.

References


